Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

Abstract Background Current evidence about the cardiovascular safety of glucagon-like peptide-1 receptor agonist (GLP-1ra) possesses limited generalizability to real-world patients with type 2 diabetes (T2D) in usual practice. This study aimed to investigate the comparative cardiovascular safety of...

Full description

Bibliographic Details
Main Authors: Chun-Ting Yang, Chen-Yi Yang, Huang-Tz Ou, Shihchen Kuo
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Cardiovascular Diabetology
Subjects:
GLP-1 receptor agonist
Cardiovascular safety
DPP-4 inhibitor
Sulfonylurea
Insulin
Online Access:http://link.springer.com/article/10.1186/s12933-020-01053-0

Internet

http://link.springer.com/article/10.1186/s12933-020-01053-0

Similar Items